“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” said Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products in the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research*
SPRAVATO® (esketamine) is a prescription medicine that comes in nasal spray, used along with an antidepressant taken by mouth, to treat:
· Adults with treatment-resistant depression (TRD)
· Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
Effective January 1, 2021, the Department of Social Services (DSS) is implementing a Prior Authorization (PA) requirement for the coverage of esketamine nasal spray, marketed as Spravato®, for HUSKY A, HUSKY B, HUSKY C, and HUSKY D members.
Due to the risks for sedation and dissociation and the potential for misuse, Spravato® is only available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (REMS).